CinDome Pharma announces successful completion of thorough QT study of CIN-102 (deudomperidone) in healthy subjects. CIN-102, Deudomperidone, is a novel, deuterium-containing, peripherally selective dopamine (D2/D3) receptor antagonist.Study demonstrated that therapeutic and ~5-fold supra-therapeutic concentrations...

CinFina Pharma In-Licenses Obesity Portfolio Four novel, once-weekly anorectic agents targeting significant weight lossCINCINNATI, Sept. 22, 2021 (GLOBE NEWSWIRE) -- CinFina Pharma, LLC. (“CinFina”) announced today that it has signed an...

CinDome Pharma Announces Start of Phase 2 Trial of Deuterated Domperidone (CIN-102) CINCINNATI, Sept. 19, 2019 (GLOBE NEWSWIRE) -- CinDome Pharma, Inc. (“CinDome”), a company whose lead product is deuterated domperidone (CIN-102), today announced that is has enrolled the first...

CinRx Closes $10 Million Series B Financing CINCINNATI, Nov. 28, 2017 (GLOBE NEWSWIRE) -- CinRx, a biopharmaceutical company with an innovative approach to developing novel therapeutics that address diverse therapeutic areas, announced today...